GVAX leukemia vaccine

GVAX leukemia vaccine is an autologous cell-based immunotherapy consisting of a patient's own leukemia cells that have been genetically modified to secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and then irradiated. The vaccine is designed to stimulate a systemic immune response against leukemia-associated antigens. Upon intradermal administration, the secreted GM-CSF recruits and activates dendritic cells to the injection site. These antigen-presenting cells then ingest the irradiated tumor cells, process the full spectrum of tumor-specific antigens, and migrate to regional lymph nodes to prime T-cell responses. This approach aims to eliminate minimal residual disease and prevent relapse in patients with acute myelogenous leukemia (AML) or chronic myelogenous leukemia (CML).

Brand names

GVAX

Other names

GM-CSF-secreting leukemia vaccineautologous GM-CSF-secreting leukemia vaccineAML-GVAX